R. Kuniyoshi

发表

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.

S. Matsusaka, Y. Mishima, K. Hatake, 2012, International immunology.

Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients

K. Chìn, T. Takayama, S. Matsusaka, 2017, Targeted Oncology.

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma

S. Sakajiri, T. Sakurai, Y. Mishima, 2009, Clinical Cancer Research.

Identification of CD 20 C-Terminal DeletionMutations Associated with Loss of CD 20 Expression in Non-Hodgkin ’ s Lymphoma

S. Sakajiri, T. Sakurai, K. Takeuchi, 2009 .

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer

S. Matsusaka, K. Hatake, Y. Terui, 2011, Cancer science.

Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast.

T. Kasahara, Y. Sonoda, Y. Mishima, 2006, Biological & pharmaceutical bulletin.

Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors

S. Kimura, T. Takizawa, K. Ozawa, 2008, Cancer science.

Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab

S. Matsusaka, Yuji Mishima, Satoshi Matsusaka, 2011, Cancer.

Sumoylation and Apoptosis

Y. Mishima, K. Hatake, Y. Terui, 2009 .

Combination of chloroquine treatment has possibility of overcome T315I mutated Ph + ALL cells: establishment of two cell lines of double Ph + ALL with or without T315I mutation from one clinical course.

Y. Mishima, K. Hatake, Y. Terui, 2011 .

Continuous treatment of bestatin induces anti‐angiogenic property in endothelial cells

K. Hatake, Natsuhiko Sugimura, Y. Terui, 2007, Cancer science.